2487 Stock Overview
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cutia Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$16.64 |
| 52 Week High | HK$24.00 |
| 52 Week Low | HK$5.57 |
| Beta | 0 |
| 11 Month Change | 29.80% |
| 3 Month Change | 171.01% |
| 1 Year Change | -16.80% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2487 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 13.7% | 18.1% | 13.0% |
| 1Y | -16.8% | -1.6% | 16.1% |
Return vs Industry: 2487 underperformed the Hong Kong Biotechs industry which returned -7.9% over the past year.
Return vs Market: 2487 underperformed the Hong Kong Market which returned 13.4% over the past year.
Price Volatility
| 2487 volatility | |
|---|---|
| 2487 Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2487's share price has been volatile over the past 3 months.
Volatility Over Time: 2487's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 360 | Lele Zhang | www.cutiatx.com |
Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company’s products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis.
Cutia Therapeutics Fundamentals Summary
| 2487 fundamental statistics | |
|---|---|
| Market cap | HK$5.06b |
| Earnings (TTM) | -HK$580.79m |
| Revenue (TTM) | HK$220.26m |
23.0x
P/S Ratio-8.7x
P/E RatioIs 2487 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2487 income statement (TTM) | |
|---|---|
| Revenue | CN¥198.86m |
| Cost of Revenue | CN¥98.77m |
| Gross Profit | CN¥100.08m |
| Other Expenses | CN¥624.43m |
| Earnings | -CN¥524.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 50.33% |
| Net Profit Margin | -263.68% |
| Debt/Equity Ratio | 17.7% |
How did 2487 perform over the long term?
See historical performance and comparison